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Abstract 
Maternal consumption of a Western diet (WD) has been linked to alterations in fetoplacental 
metabolic programming and risk for the exposed fetus to develop obesity, cardiovascular 
disease, and type II diabetes mellitus.   It may also cause oxidative damage to the placental 
mitochondria.  This thesis investigated the metabolic effects of a WD on placentae using a 
guinea pig model of pregnancy and hyperpolarized 13C MRI for metabolic quantification.  It 
was hypothesized that placental glycolytic metabolism would increase, and placental 
oxidative metabolism would decrease in WD-fed sows.  Control diet- and WD-fed, pregnant 
sows underwent metabolic MRI at 33 days gestation and were investigated by quantifying 
the placental lactate-, alanine-, and bicarbonate-to-pyruvate ratios.  A statistically significant 
relationship was detected between placental appearance and metabolism that could be useful 
as a biomarker of fetoplacental health. These results reinforce the importance of placental 
metabolic research to determine the relationship between WD consumption and placental 
metabolism. 
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Summary for Lay Audience 
This thesis investigated the effects of eating a high-fat, high-sugar diet during pregnancy. 
This type of diet is known as the Western diet (WD). The placenta is a temporary but critical 
organ of pregnancy that can be affected by a WD.  The placenta supports the baby’s growth 
and development and provides nutrients. Eating a WD has the potential to impact our short- 
and long-term health negatively. Eating a WD can alter epigenetic mechanisms. These 
mechanisms influence how our bodies respond to and process the foods we eat. Changes to 
these mechanisms predispose a person to develop adverse health conditions. Eating a WD 
exposes the placenta to a toxic environment. This toxic environment may damage cellular 
structures and mechanisms involved in metabolism. It alters the processes our bodies use to 
derive energy from food. This study sought to detect these changes early in pregnancy. Early 
detection of these changes could be useful as a diagnostic tool. A diagnostic tool would be 
useful for understanding and detecting babies in metabolic distress.  It was expected that 
eating a WD would result in less efficient methods of energy production. This study 
investigated metabolic changes in the placenta.  A guinea pig model of pregnancy was used 
because guinea pigs have a similar placental structure and function to the human placenta. 
Guinea pigs were fed either a WD or a control diet.  At mid-pregnancy, guinea pigs 
underwent specialized MRI techniques to measure metabolism and assess the physical 
characteristics of the placenta. No significant relationship was detected between diet and 
metabolism.  However, a significant relationship was detected between placental 
characteristics and metabolism, and this relationship may be a useful indicator of a baby’s 
health.  Future work should include the collection of extra mid-pregnancy data. 
Understanding babies in metabolic distress is critical to our short- and long-term health.  
Future studies need to clarify the relationship between diet and a baby's health. 
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Chapter 1  
1 Introduction 
This thesis introduction begins by describing the normal progression of pregnancy, as 
well as complications that may be encountered during pregnancy. Next, in utero 
environmental exposures and obesity and its effects during pregnancy are examined.  
Third, this thesis provides background information on the Western diet, metabolic 
programming, and placental development, role, and metabolism.  Additionally, current 
monitoring methods of fetoplacental health and hyperpolarized magnetic resonance 
imaging are described.  Last, this introduction examines analysis methods and animal 
models.   
1.1 Pregnancy 
Pregnancy in humans refers to the period during which a fetus develops within a female’s 
uterus. A typical gestational period is approximately 40 weeks and is measured from the 
first day of the last menstrual period (LMP) to delivery. The gestational age (GA) of a 
fetus refers to the current duration of pregnancy. It is counted from the first day of the last 
menstrual period. GA is usually expressed in weeks and days, and pregnancy is 
commonly divided into three trimesters. The first trimester lasts from zero days LMP to 
the end of the 13thweek of pregnancy. This trimester encompasses events such as rapid 
cell divisions, placentation, and embryonic organogenesis. The first trimester of 
pregnancy is a critical period of development, during which time the embryo/fetus is 
particularly sensitive to disruptions in its environment and development. The second 
trimester lasts from 14 weeks to the end of the 27th week [1]. During this period, we see 
continued development of the fetal form and function [2] and a fully developed and 
functioning placenta [1].  The third trimester lasts from the 28th week of pregnancy until 
delivery. By this time, the fetus is mostly developed and gains weight rapidly [2], 
attributable primarily to the increasing development of subcutaneous adipose tissue [3]. 
The placenta, while still supporting the fetus, matures and follows a normal path of 
decline approaching the delivery of the fetus, which marks the end of pregnancy [1]. 
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1.1.1 Placenta 
The placenta is a fetal organ that exists only during pregnancy and acts as an interface 
between the maternal and fetal environment to support fetal growth and development. 
Anatomically, the placenta has a “maternal side,” known as the basal plate and a “fetal 
side,” known as the chorionic plate. The basal plate is formed by the decidua basalis, 
which is the term given to the layer of decidua that lies deep to the conceptus. The 
decidua is the term given to the functional layer of endometrium in a gravid uterus [1]. 
The chorionic plate is composed of the amniochorionic membrane and fetal vessels [4]. 
The human placenta is known to be hemochorial in structure, meaning that there is a 
single layer of chorionic cells (syncytiotrophoblasts) separating maternal and fetal 
circulation of red blood cells [5]. 
 
Typically, the placenta is a flattened, circular, metabolically active, highly vascularized 
and low-resistance organ that weighs approximately 600 grams at term and is 2-4cm 
thick depending on gestational age. It can attach to the uterine wall anywhere within the 
uterine cavity, with the maternal side being comprised of nearly 20 functional lobes 
composed of maternal sinusoids and chorionic villous structures. Generally, the placenta 
has a homogeneous tissue texture and smooth borders with central insertion of the 
umbilical cord - the vascular connection between the fetus and placenta. 
 
The retroplacental complex is a 20cm-thick, vascularized zone just deep to (or 
underneath) the basal plate of the placenta and is composed of decidua basalis, uterine 
myometrium, and maternal veins, which drain the placenta [1].  The gross placental 
structure and umbilical cord can be seen in Figure 1.  
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Figure 1: The placenta (figure adapted [6, 7]).  The umbilical cord is seen inserting 
into the placenta.  The chorionic plate is seen on the fetal side, and the basal plate is 
seen on the maternal side of the placenta. 
1.1.1.1 Placental Development 
The placenta is composed of parenchyma, chorion, amnion, and the umbilical cord. The 
trophoblast is formed from the trophectoderm.  Contact between the endometrium and the 
trophoblast, during implantation of the blastocyst, initiates the development of the 
syncytiotrophoblast and the cytotrophoblast. The cytotrophoblast secretes enzymes that 
erode the endometrial cells and allows for invasion of the endometrial wall by 
syncytiotrophoblast cells [4]. 
 
The placenta is formed by the chorion, which is composed of syncytiotrophoblast, 
cytotrophoblast, and extraembryonic mesoderm.  The syncytiotrophoblasts and 
cytotrophoblasts are specialized placental cells that line the chorionic villi. The 
cytotrophoblast pushes into the syncytiotrophoblast, forming finger-like projections 
called the primary chorionic villi.  The secondary chorionic villi are formed when the 
extraembryonic mesoderm divides into splanchnic and somatic mesoderm. The 
completed formation of blood cells and vessels from mesenchyme marks the presence of 
tertiary chorionic villi.  A vascular network then develops from the villi connecting to the 
chorionic 
plate 
umbilical 
cord 
basal plate 
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embryonic heart as the villi continue to grow and branch into the chorion, bathed in 
maternal blood in the intervillous spaces from remodelled maternal uterine spiral arteries 
in each of the functional lobes of the placenta.  As placental development continues, the 
amnion and chorion fuse.  Together with the fetal vessels, this forms the chorionic plate 
of the placenta.  By the third month of pregnancy, the placenta is fully developed and is 
functioning to support the developing fetus [4]. 
1.1.1.2 Role of the Placenta 
The placenta is considered to be an immune and endocrine organ that functions to support 
fetal growth and development by acting as an interface between maternal and fetal 
environments.  The exchange of maternal and fetal substances occurs across the chorionic 
membrane of the villi and the intervillous spaces containing maternal blood. Oxygen and 
carbon dioxide, hormones, maternal antibodies, electrolytes, fetal waste, and nutrition for 
the fetus in the form of amino acids, water, vitamins, free fatty acids, and glucose are 
exchanged across the membrane [4].  Figure 2 demonstrates placentation. 
 
Figure 2: Placentation [8, 9].  The chorionic villi are seen deep to the chorion, 
surrounded by the intervillous spaces and bathed in maternal blood for the 
exchange of nutrients, gases, and waste. 
1.1.1.3 Placental Metabolism 
Metabolically, the placenta serves to produce glycogen (from maternal glucose) and 
cholesterol (from maternal fatty acids).  The cholesterol produced is used to generate 
5 
 
hormones like estrogen, progesterone, and glucocorticoids that help to sustain the 
pregnancy and influence fetal development [4].  The placenta also synthesizes peptide 
hormones such as vascular endothelial growth factor (VEGF) and placental growth factor 
(PIGF), which have a role in placental development and maternal spiral artery 
remodelling [10]. Glycogen produced in the placenta is stored for use as energy for the 
fetus [4]. 
 
While the placenta provides energy via glycogen storage to the fetus, the placenta itself 
requires energy from glucose to function.  The fetal environment is known to be naturally 
hypoxic [11], and levels of oxygen in the placenta during the first trimester are also 
naturally low [12]. In this low-oxygen state, energy for the placenta is derived from the 
production of lactate through aerobic glycolysis [13]. 
 
The presence of an adverse maternal metabolic environment has the potential to alter the 
normal metabolic processes and efficiency of the placenta.  Some studies have shown that 
a high fat, high sugar maternal environment leads to abnormal accumulation of lipids in 
the placenta and also suggest that exposure of the placenta to a lipotoxic environment 
may lead to oxidative damage to placental mitochondria, the cellular organelles 
responsible for placental metabolism and energy production [14, 15]. 
1.1.1.4 The Uterus 
The uterus is a muscular organ that forms part of the female reproductive system. The 
uterus is where implantation and growth of a conceptus occurs and plays a significant 
role in the labour and delivery of a fetus by producing strong muscle contractions that 
ultimately expel the fetus from the uterus during the birthing process.  There are four 
segments to the uterus - the fundus, the corpus, the isthmus, and the cervix.  The uterus 
contains an internal cavity, which is lined with endometrium - a mucosa, which is the 
innermost of three uterine layers of tissue.  The outermost layer is the serosa, which is 
thin. The middle layer is the thick, muscular layer called the myometrium [1]. 
 
The endometrium is a specialized mucosal tissue that responds to changes in hormone 
levels throughout the menstrual cycle by altering its thickness and composition to 
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accommodate and support the implantation of a fragile conceptus.  The endometrium has 
two layers: a superficial functional layer and a deep basal layer.  It is the functional layer 
of the endometrium that is termed the decidua in the gravid uterus.  The decidua is further 
subdivided based on its anatomical relationship to the implanted conceptus.  The decidua 
basalis is deep to the conceptus, and the decidua capsularis overlies the conceptus. 
Finally, the decidua parietalis refers to all remaining portions of the decidua [1].  Figure 3 
demonstrates the anatomy of the uterus. 
 
Figure 3: The uterus (figure adapted [16, 17]).  The uterine cavity, fundus, body, 
and cervix are demonstrated in this figure. 
1.1.2 Uncomplicated vs. Complicated Pregnancies 
Many pregnancies progress without complication, resulting in the uncomplicated births 
of normally developed and functioning, healthy babies.  However, there are many 
pregnancies plagued by complications relating to maternal health before and during 
pregnancy.  Fetal development and environment, including in utero exposures to toxins, 
viruses, and adverse maternal environment, can also lead to complications in pregnancy.  
Additional complications may arise during delivery or following delivery in the postnatal 
period [1]. 
fundus fallopian tubes 
ovary 
uterine cavity 
uterus 
body of uterus 
cervix 
vagina 
cervical canal 
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1.1.3 Common Complications in Pregnancy 
During pregnancy, there are many sources for complications, which may arise from 
maternal and/or fetal health status.  Some of the more common or serious complications 
include maternal and fetal exposures to infectious disease, diabetes mellitus, maternal 
hypertension, preeclampsia, intrauterine growth restriction (IUGR), preterm labour, and 
pregnancy miscarriage and stillbirth [18]. Conditions such as diabetes, IUGR, and 
macrosomia are potentially associated with metabolic dysregulation, which may affect 
metabolic regulation in the fetoplacental unit. 
 
Infections with the potential to affect the healthy development and outcome of a 
pregnancy include some sexually transmitted infections and infections such as varicella 
and rubella [1].  These infections can pass from mother to fetus during pregnancy or can 
be passed on to the neonate via the birth canal in a vaginal delivery.  Some of the 
consequences of maternal infection during pregnancy are a congenital anomaly in the 
neonate, low birth weight, miscarriage and stillbirth, and neonatal death.  Luckily, many 
of these infections can be prevented or treated and managed with appropriate medical 
care before and during pregnancy [1, 18].  
 
Diabetes mellitus, a disorder of carbohydrate metabolism, associated with a deficiency in 
insulin and characteristic hyperglycemia, can be classified into several types.  Some of 
the more familiar types are type I, type II, and gestational diabetes. 
Gestational diabetes mellitus only occurs during pregnancy, while other types may occur 
outside of pregnancy and can persist during pregnancy [1]. 
 
Having diabetes mellitus during pregnancy is associated with fetal congenital anomalies 
in the skeletal, central nervous, cardiac, renal, and gastrointestinal systems and anomalies 
in the umbilical cord, as well as a 15-20% spontaneous abortion rate. These anomalies are 
associated with high blood sugar levels, as in hyperglycemia, which disrupts embryonic 
organogenesis leading to anomalous organ system development. Diabetes mellitus in 
pregnancy may also lead to abnormal growth conditions such as IUGR and macrosomia. 
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IUGR is commonly defined as an “estimated fetal weight less than the 10th percentile for 
the gestational age”, but this is not the only accepted definition. Unfortunately, the 
existence of several definitions for IUGR contributes to a lack of consistency in diagnosis 
[1].  Consistency in diagnosis and appropriateness of definitions for the diversity of the 
population may also be relevant to the definition and diagnosis of macrosomia in light of 
racial, genetic, and sex differences [19, 20]. 
 
Fetuses diagnosed with IUGR have increased risk of perinatal mortality and are more 
likely across their lifespan to develop conditions such as hypertension, cardiovascular 
disease, diabetes mellitus, and obesity.  Fetal development of IUGR is more prevalent in 
women with hypertension, and preeclampsia is associated with the most severe growth 
deficits in terms of maternal factors that may influence fetal growth restriction.  IUGR in 
fetuses of diabetic mothers is attributed to uteroplacental vascular insufficiency in which 
there is less maternal blood reaching the fetus through the placenta carrying critical 
nutrients and oxygen needed for normal growth [1]. 
 
Macrosomia in a fetus is defined as a fetal weight greater than 4500 grams or a birth 
weight above the 90th percentile for gestational age. It may result from fetal 
hyperinsulinemia (excessive insulin), as excessive sugars from maternal hyperglycemia 
enter the fetal circulatory system through the placenta and stimulate fetal insulin 
production [21].  Fetal hyperinsulinemia prompts increased growth of body tissues, 
including adipose tissue.  Macrosomic fetuses are predisposed to stillbirth and 
intrapartum trauma, such as shoulder dystocia [1].  Similar to fetuses with IUGR, 
macrosomia predisposes a fetus to cardiovascular and metabolic conditions across their 
lifespan, including diabetes mellitus and obesity [3, 20].  Risk factors for developing fetal 
macrosomia include maternal diabetes mellitus (type I, II, or gestational), excessive 
maternal weight gain, and obesity [1]. 
 
Maternal hypertension (high blood pressure) is associated with co-morbidities such as 
diabetes mellitus and obesity [22] and may exist before pregnancy or may develop during 
pregnancy.  If, in addition to hypertension, proteinuria and/or edema develop, we call this 
toxaemia of pregnancy or preeclampsia.  Preeclampsia can increase the prenatal mortality 
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rate and can also develop into the more severe eclampsia involving maternal convulsions 
and a significant increase in fetal and maternal mortality [1].  Conditions associated with 
preeclampsia include fetal distress, low birth weight, and placental abruption.  While the 
etiology of preeclampsia is unclear, hormonal, immunologic, and diet-related factors are 
considered to be contributors to its development.  The proposed etiologic factors are 
likely responsible for the placental vascular disease and reduced uteroplacental blood 
flow seen in preeclamptic patients, leading to limited oxygen and nutrient delivery to the 
fetus via the placenta and ultimately leading to unfavourable outcomes [1]. 
 
In summary, there are fetal, maternal, and placental factors intimately intertwined with 
the external and internal maternal environment, including diet, which can lead to a 
complicated pregnancy. 
1.1.4 Importance of Environmental Exposures During Pregnancy 
Exposure to toxins and other harmful agents can come from interactions with other 
people in the form of viruses and bacteria, as well as from polluted air, contaminated 
water, inhaled or ingested substances, and the foods we consume [1, 23-25].  All of these 
sources have the potential to negatively impact our health in the short-and long-term, 
with pregnant women and their fetuses being no exception.  In utero exposure to these 
environmental factors can have obvious and disabling effects upon the fetus as in fetal 
alcohol syndrome that results from alcohol consumption during pregnancy.  They can 
also have silent, insidious effects on the fetus, such as the epigenetic changes to 
metabolic programming seen with maternal consumption of a poor diet and poor maternal 
metabolic health [26]. 
1.1.4.1 Importance of Maternal Environment 
The concept of the developmental origins of health and disease (DOHaD) postulates that 
exposure to some environmental factors during crucial periods of growth and 
development could have a significant impact on the short- and long-term health of an 
individual.  This concept suggests that when a developing fetus is exposed to an 
inhospitable uterine environment, caused by insults such as poor nutrition, chemicals, or 
metabolic and hormonal dysregulation, it responds by developing adaptations to ensure 
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its survival in the short term, but also its survival should a similar environment arise later 
in life [27]. 
 
The quality of the time a fetus spends in utero is critical to its healthy growth and 
development and the quality of life of the individual across their lifespan.  Since the fetus 
is exposed, through the placenta, to the maternal environment, we must consider the 
effect that maternal constitutional factors have on the fetus and placenta.  Constitutional 
factors refer to a basic physiological tendency that affects the etiology of specific 
physical conditions, for example, physiological characteristics relating to circulatory and 
metabolic function.  The maternal diet consumed before and during pregnancy can affect 
constitutional factors relating to maternal cardiometabolic health.  Previous studies have 
shown that both maternal under and overnutrition can result in altered fetoplacental 
metabolic programming, perhaps as an adaptive mechanism to prepare for the presumed 
adverse environment [28] after birth.  Some diets, such as the Western diet (WD), are 
calorie-dense and nutritionally deficient and are associated with the development of 
overweight and obesity, type II diabetes mellitus (DM), cardiovascular disease, and 
deposition of excess dietary energy.  This excess dietary energy is stored as fat in ectopic 
and cardiometabolically unhealthy fat storage depots in the body, such as intraabdominal 
fat stores and intra-organ fat stores (e.g. the storage of excess lipid in the hepatocytes of 
the liver).  Previous studies have shown that obesity, diabetes mellitus, and chronic 
consumption of high fat, high sugar diets, such as the WD, lead to a lipotoxic and 
hyperglycemic environment with the potential to impact placental development and 
function negatively, and subsequently impact fetal health and programming outcomes 
[15, 29]. 
 
In summary, the quality of our in utero environment can affect our lifetime health and 
quality-of-life trajectory, beginning with the placenta - the interface between maternal 
and fetal environments. 
1.2 Metabolism 
Metabolism refers to the chemical reactions that take place within our bodies to provide 
our cells with energy, as required, to maintain homeostasis and sustain life [30].  
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Anabolic metabolism is the generation of larger molecules from smaller subunits, as in 
the formation of glycogen from glucose for storage of energy.  Catabolic metabolism 
refers to the “breakdown” or oxidation of macronutrients, such as fats and carbohydrates, 
for the production and use of energy in the form of adenosine triphosphate (ATP) [30]. 
Energy balance must be reached to achieve homeostasis, meaning that our energy intake 
from macronutrients must be in balance with the oxidation of those macronutrients.  
While fats are a high-energy fuel, our dietary need for them is low, and most dietary fat 
intake is stored in adipose tissue and not oxidized for use as energy unless energy 
generation from carbohydrate intake is insufficient to meet daily energy requirements. 
Carbohydrates are the primary fuel source for energy production in humans and can be 
metabolized to a usable form via several pathways, with the fundamental molecular unit 
being glucose.  If the composition of an individual’s diet is changed, metabolic flexibility 
may allow the body and cells to match the oxidation of fuels to the availability of fuels.  
Impairment of this metabolic flexibility may lead to increased dietary energy intake to 
maintain homeostasis.  An obese state sees excess glucose converted to triglycerides via 
lipogenesis and stored in adipocytes.  In a state of lipotoxicity, triacylglycerol 
accumulates in the lipid droplets of hepatocytes, skeletal muscle, and pancreatic beta 
cells.  This accumulation in the lipid droplets is a significant factor in the pathogenesis of 
insulin resistance, type II DM, and metabolic syndrome [31]. 
1.2.1 Metabolic Pathways 
There are specific metabolic pathways for each type of macronutrient we consume. 
Dietary carbohydrates are broken down to glucose in most cases and enter either a non-
oxidative or oxidative pathway.  The metabolic pathway which will be utilized is 
determined by the presence or lack of oxygen, type of cells composing the tissue, and the 
intracellular energy level. 
 
In the presence of oxygen, mitochondria, and a cellular need for energy, glucose 
oxidation begins with the formation of two pyruvate molecules from a single glucose 
molecule via glycolysis.  Following this, decarboxylation of pyruvate occurs, producing 
two molecules of acetyl coenzyme A (acetyl-CoA), which can then be used in the 
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tricarboxylic acid (TCA) cycle.  The TCA cycle is also called the citric acid cycle and the 
Krebs cycle.  This decarboxylation process links glycolysis and the TCA cycle.  
Following the TCA cycle, oxidative phosphorylation occurs, from where the majority of 
ATP produced via aerobic respiration is derived [30]. 
 
In the absence of oxygen, or in cells without mitochondria, the anaerobic respiratory 
process of glycolysis occurs.  Pyruvate is converted to lactate or alanine via enzymatic 
activity to produce, albeit much less efficiently than aerobic respiratory processes, 
cellular energy.  The process of glycolysis occurs in the cellular cytoplasm. Pyruvate is 
converted to lactate via the enzyme, lactate dehydrogenase (LDH).  Alanine is derived 
from pyruvate in a transamination process that uses the catalyzing enzyme alanine 
aminotransferase (ALT). 
 
As mentioned previously, pyruvate can also be converted to acetyl-CoA via the enzyme 
pyruvate dehydrogenase (PDH) in the PDH reaction, which occurs in the mitochondria. 
Carbon dioxide (CO2), a waste product of this reaction, is in equilibrium with cellular 
bicarbonate.  Insulin stimulates this reaction and consequently also stimulates the TCA 
cycle.   
 
The TCA cycle also occurs within the mitochondria and is a biodegradation process that 
begins with the joining of oxaloacetate to acetyl-CoA, forming the TCA cycle 
intermediate, citrate.  As the cycle continues, multiple intermediates are generated 
through enzymatic reactions.  The cycle ends where it began with oxaloacetate, having 
generated high-energy coenzymes and by-products such as CO2.  
 
The oxidative phosphorylation (OXPHOS) reaction, occurring in the mitochondria, 
oxidizes reduced, high-energy coenzymes, such as nicotinamide adenine dinucleotide 
(NADH2), via the release of its hydrogen.  The energy from hydrogen’s electron is slowly 
transferred to oxygen through a series of enzymatic reactions.  These enzymes use the 
energy released to generate a proton gradient across the inner mitochondrial membrane 
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(IMM), which ultimately provides the energy for ATP generation.  Water and CO2 are 
produced as by-products of OXPHOS [30].   
 
Overall, a theoretical 38 ATP molecules are produced from one glucose molecule via 
cellular respiration.  In contrast, glycolysis- whether aerobic or anaerobic, produces only 
2 ATP molecules per glucose molecule consumed in the process.  
 
Given that these processes are regulated by factors such as insulin and intracellular 
energy levels, metabolic conditions that alter these factors can drastically change the 
pathway for carbohydrate metabolism and also result in changes to the metabolic 
pathways for other macronutrients, such as fats [30].  
 
Recognizing that placental health is critical to fetal development and that the placenta is a 
poorly understood organ, it is paramount that we continue to broaden our understanding 
of placental development and function - including metabolism, particularly in conditions 
of metabolic dysregulation. 
1.2.1.1 Pyruvate 
In this thesis, the interest was in the metabolic fate of intravenously injected, supra-
physiological concentrations of a hyperpolarized, carbon-13-labelled pyruvate (13C-
labelled pyruvate) solution (labelled in the C1 position) for two main reasons. First, 
understanding that glucose is the primary fuel for our bodies’ cells, metabolic pathways 
for carbohydrate metabolism are of critical importance.  As has been outlined, pyruvate is 
the product of the partial oxidation of glucose during glycolysis, making it an integral 
component in the process of cellular energy production from glucose.  Second, pyruvate’s 
intersection with the LDH reaction, transamination to alanine, and PDH reaction- leading 
to the TCA cycle, allows for quick, quantitative probing of these pathways [30].  Figure 4 
demonstrates the location in the cell where the 13C1-labelled reactions of interest take 
place. 
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Figure 4: Metabolic Pathways of Pyruvate [32].  Pyruvate can be converted to 
alanine or lactate in the cytoplasm, or it can enter the mitochondria and produce 
bicarbonate as a by-product of aerobic cellular respiration pathways.  The 13C1 label 
is indicated on pyruvate and its metabolites and by-products. 
1.3 Metabolic Programming 
The predisposition of the offspring of diabetic and/or obese mothers to developing 
cardiometabolic conditions later in life is likely the result of early programming of fetal 
organ structure and metabolism due to an unfavourable fetal nutritional environment. In 
utero exposure to overnutrition (excess dietary glucose and fat) likely alters early-
pregnancy processes like epigenetic changes via DNA methylation, placentation, and 
fetal organogenesis [28].  These changes result in permanent metabolic abnormalities in 
fetal metabolic tissues and organ systems with a subsequent predisposition to 
cardiometabolic disease.  This process is known as metabolic programming. 
 
As previously discussed, conditions such as diabetes mellitus and obesity can lead to 
macrosomic fetuses or fetuses with increased birth weight owing, in part, to an increase 
in adipose tissue development.  The hyperglycemic maternal environment stimulates the 
fetal pancreas to produce insulin, and the fetus subsequently develops hyperinsulinemia, 
prompting increased development and deposition of adipose tissue.  Interestingly, some 
studies have shown that any increase in maternal glucose concentration, even in the 
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normal range, is associated linearly with increased fetal adiposity and birthweight [33].  
There is also evidence to suggest that these increases in maternal glucose concentration 
within the normal range may also predispose the exposed fetus to develop diabetes 
mellitus, overweight, and obesity, independent of maternal BMI [34]. 
1.3.1 Cardiovascular Disease (CVD) 
CVD is the number one cause of death worldwide and is composed of a group of 
disorders affecting the heart and blood vessels of the body.  Coronary heart disease, 
cerebrovascular disease, peripheral arterial disease, and deep vein thrombosis are all 
examples of CVDs.  Risk factors for developing CVD include consumption of a poor 
diet, physical inactivity, obesity, tobacco use and genetic factors.  Two serious 
consequences of CVD are myocardial infarction (heart attack) and cerebrovascular 
accident (stroke) most often caused by a narrowing of the blood vessels supplying the 
heart or brain due to atherosclerosis.  Atherosclerosis is the accumulation of fatty deposits 
within the blood vessel walls [35].  
1.3.2 Type II Diabetes Mellitus (Type II DM) 
Type II DM is a leading cause of death in North America, and the global prevalence of 
the disease is rapidly rising.  It is characterized by abnormally high levels of glucose in 
the blood and reduced sensitivity of the body’s cells to insulin, known as insulin 
resistance.  Normally, when levels of glucose are increased in the blood, the pancreas is 
stimulated to release insulin.  Circulating insulin controls glucose levels and drives 
glucose from the blood into cells for use as energy or storage once energy needs for the 
body are met.  With type II DM, the body’s cells are not as responsive to insulin, and 
excess glucose remains in the blood.  As this resistance to insulin develops, beta cells in 
the pancreas produce more insulin to normalize blood glucose levels.  Eventually, the 
pancreatic beta cells become less capable of responding to fluctuations in blood glucose 
levels, and there is a shortage of insulin.  This insulin shortage prevents the effective 
reduction of glucose levels in the blood.  
 
The aging process and genetic factors involving gene expression are associated with an 
increase in the risk of developing type II DM and will exacerbate the metabolic 
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dysregulation characteristic of the condition.  Other factors such as poor diet, overweight 
and obesity, and physical inactivity also increase the risk and exacerbate the metabolic 
dysregulation.  However, these factors also increase the risk of developing type II DM at 
any age.  Uncontrolled type II DM can lead to severe health conditions such as CVD and 
eye, nerve, and renal damage [36]. 
1.3.2.1 Fatty Liver Disease 
Fatty liver disease refers to the excessive accumulation of lipids within hepatocytes above 
5% of the total liver volume.  Non-alcoholic fatty liver disease (NAFLD) refers to the 
condition where this abnormal accumulation of lipid in the liver cells is not attributable to 
alcohol consumption. Instead, the likelihood of developing NAFLD increases with being 
overweight or obese, with fat accumulation centred around the waist.  Developing 
NAFLD is also associated with having type II DM and consuming a diet high in saturated 
fat and refined sugars regardless of BMI.  As the liver processes sugars and fats from 
dietary intake for use as energy for the body, excesses are stored as lipids in the 
hepatocytes.  This process may lead to enlargement of the liver and, eventually, the 
hepatic inflammation and fibrosis characteristic of non-alcoholic steatohepatitis (NASH).  
NASH can ultimately lead to cirrhosis of the liver, chronic liver failure requiring 
transplant, and liver cancer [37]. 
1.4 Obesity 
Obesity is described as a chronic and progressive disease where excessive fat 
accumulates in the body that may harm our health.  According to a 2014 health survey, 5 
million Canadians were living with obesity, and that number is expected to increase over 
the next two decades.  The annual direct healthcare cost for obesity-related medical care 
is approximately 7 billion dollars, and this cost is expected to rise to 9 billion dollars by 
the year 2021 [38]. 
 
Obesity is commonly measured using the body mass index (BMI).  It is measured by 
dividing an individual’s weight in kilograms (kg) by their height in metres squared (m2), 
giving a result expressed in kg/m2.  This result is then compared to a weight classification 
BMI chart to determine an individual’s weight classification.  A BMI above 30 kg/m2 is 
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generally accepted to represent obesity in the Caucasian population - though this is only a 
measure of size and not health.  Other factors, such as waist circumference, waist-to-hip 
ratio, and the presence of associated co-morbidities, should also be considered when 
making a formal medical diagnosis of obesity.  A diagnosis of obesity is associated with 
the consumption of a Western diet and is also associated with co-morbidities such as type 
II diabetes mellitus, hypertension, cardiovascular disease, and infertility [38, 39]. 
 
As the rates of obesity in the general population increase, obesity rates in females of 
child-bearing age also continue to rise.  Obese pregnancies are considered by the medical 
community to be “high risk” for serious maternal and fetal complications [40]. 
1.4.1 Obesity and Pregnancy 
Obesity during pregnancy is the most common pre-existing health condition encountered 
by health professionals.  The risk of developing conditions such as gestational diabetes 
mellitus and preeclampsia is increased in obese women when compared to normal-weight 
women.  As such, fetal congenital anomalies, early spontaneous abortions, and IUGR and 
macrosomic fetuses are more likely to occur in obese women.  Infertility is also more 
prevalent in obese women than in normal BMI women. This increased prevalence may be 
due to changes in the menstrual cycle, the quality of oocytes ovulated from the ovaries, 
and an unfavourable endometrial environment for implantation and development of the 
conceptus within the uterus [19]. 
Obesity in pregnancy is implicated in long-term effects on the fetus. Early pregnancy 
alterations to fetoplacental metabolic programming can increase the risk in the offspring 
of developing conditions such as type II diabetes mellitus, cardiovascular disease, and 
obesity throughout their lifespan. This increased risk seems to be the result of metabolic 
dyregulation in the maternal environment.  Increased insulin resistance results in 
decreased uptake of glucose into the tissues for energy metabolism.  Subsequent 
increases in lipolysis for energy metabolism contribute to a lipotoxic environment and 
represent a dysregulated metabolic state.  It is thought that this metabolic dysregulation is 
a contributing factor to the epigenetic changes in fetoplacental metabolic programming 
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and may even be damaging to the placental tissues, affecting the development and 
function of the placenta [19]. 
1.5 Western Diet 
The term “diet” refers to the types of food habitually consumed by an individual or by a 
whole community.  The foods we consume provide us with energy and nutrients, such as 
glucose and vitamins and minerals that help our bodies to maintain homeostasis.  Our 
bodies require energy and nutrients derived from the foods we consume, to maintain 
proper growth and functioning of our organ systems and also, in times of stress, illness, 
or damage to protect us from harmful agents and repair damaged cells. 
 
The quality and composition of one’s diet are paramount to our health and a significant 
factor in whether or not we develop many largely preventable diseases, such as 
cardiovascular disease or type II diabetes mellitus.  A nutritionally complete and 
metabolically healthy diet is composed mostly of a wide variety of fruits, vegetables, 
legumes, and complex carbohydrates with relatively small amounts of meat, seafood and 
fish, and dairy.  This type of nutritionally rich diet provides us with the nutrients and 
metabolically healthy energy sources we require while being naturally low in saturated 
fats and simple carbohydrates, which are detrimental to our metabolic function [41, 42]. 
 
Over the last few decades, there has been an increasing trend towards highly processed, 
fast-food-type diets in many developed countries that are strongly associated with the 
current obesity epidemic in North America.  These diets are commonly referred to as the 
Standard American diet and the Western diet.  These diets are widely available and 
widely consumed intermittently and habitually. 
 
Typically, a WD is high in fat content, high in refined sugars, and high in red meat 
content while being low in dietary fibre and having very few fruits, vegetables, and 
legumes.  Overall, this is a nutritionally poor, calorically dense diet that is not compatible 
with our energy and nutritional requirements.  Habitual consumption of a WD is strongly 
associated with obesity, cardiovascular disease, and type II DM [43, 44].   
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Again, just as consumption of a WD has the potential to impact the health of non-
pregnant adults and children negatively, it will also likely impact the fetoplacental unit in 
a critical period of growth and development. 
1.5.1 Western Diet for an Animal Model of Pregnancy 
In this thesis, pregnant guinea pigs were used as an animal model for the human 
fetoplacental unit.  Either a control diet (CD) or a Western diet was fed ad libitum to the 
pregnant guinea pigs for their lifetime.  Both the control and Western diet feeds for the 
guinea pigs were pelleted and soy-based, with the WD being energy-dense.  Percentages 
of dietary protein, carbohydrate, and fats (PUFAs- polyunsaturated fatty acids, MUFAs- 
monounsaturated fatty acids, and SFAs- saturated fatty acids) that compose the two diets 
are designed to mimic, as closely as possible, a cardiometabolically healthy diet as a 
control and a Western diet for a guinea pig model of pregnancy [45, 46].  Figure 5 
illustrates the components of the control and Western diets. 
 
Figure 5: This figure demonstrates the percentage composition of carbohydrates, 
fats, and protein in the control and Western diets [7, 45]. 
1.6 Guinea Pig (GP) Model of Pregnancy 
There are several possible models of pregnancy.  Most notably, sheep and rodents have 
often been preferred as a model because of their similarities to the human gestational 
process and are, therefore, most apt to provide information that can be translated to the 
human gestational period [47].  However, these models have several disadvantages.  
Translational research concerning the developmental origins of health and disease 
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requires a small animal model with a relatively short life span compared to humans.  
Sheep take a longer time to reach maturity and present more significant challenges 
concerning housing and management compared to other small animal models.  Rats and 
mice, while more suitable than sheep in terms of size, complete key stages of 
development post-natally in contrast to the prenatal development seen in humans.  
Additionally, mice and rats tend to have large litters of 8-12 pups- a characteristic 
considered undesirable for clinical translation of research.  Guinea pigs (Cavia 
porcellus), another type of rodent, are small animals, have relatively smaller litter sizes of 
1-5 pups, are prenatal developers and have also emerged as a suitable model of 
pregnancy given their many structural and functional similarities to humans, as well as 
similarities in their physiological response to insults [47].  
 
While the gestational period of a guinea pig (GP) is ~69-71 days compared to the ~40-
week gestation of a human fetus, its fetal developmental timeline and process is broadly 
similar to that seen in the human fetus.  For example, the fetal GP accumulates both 
brown and white adipose tissue in utero and has a high total fat content at birth, unlike 
other rodents and sheep.  Another critical similarity to humans is the placental structure 
and function.  The GP placenta is haemomonochorial, meaning that there is a single layer 
of chorionic cells separating maternal and fetal circulation of red blood cells.  This type 
of separation between maternal and fetal blood circulation is analogous to the 
haemochorial placenta seen in humans.  Also similar to the human placenta, the GP 
placenta has deep decidual invasion and similar cell columns of the anchoring chorionic 
villi in the subplacenta, among other structural similarities.  Other rodent models lack the 
deep decidual invasion by the placenta seen in guinea pig and human pregnancy [47].   
Functionally, the placenta in GPs has similar metabolism to humans and supports the 
pregnancy through the provision of progesterone throughout the major part of pregnancy, 
similar to humans but unlike mice, rats, and sheep, who rely on progesterone produced 
from the ovaries to maintain pregnancy.  Because exposures to insults, such as an adverse 
maternal environment, can occur at a similar developmental stage, in a similar in utero 
environment, and with similar physiological responses to insults, the pregnant GP is 
considered to be an excellent model of human pregnancy [47]. 
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1.6.1 Western Diet Association 
It has been established that the metabolic dysregulation seen with obesity during 
pregnancy can alter fetoplacental processes leading to unfavourable outcomes of 
pregnancy in the short and long term.  The ongoing rise in rates of overweight and 
obesity in the developed world is strongly associated with the consumption of a Western 
diet, high in saturated fats and refined sugars and low in nutritional quality.  It is 
acknowledged in the literature that while there are relatively fewer studies focussed on 
the effects of a nutritionally poor, calorie-dense diet on the fetoplacental unit, this type of 
diet likely exerts an independent effect on the fetoplacental unit regardless of other 
factors [26]. 
1.7 Current Monitoring Methods of Fetoplacental 
Health 
Currently, clinical monitoring of the health of a pregnancy is centred around a patient 
interview and manual examination by a specialized health care provider.  Referral for 
laboratory tests and ultrasound examinations are routine protocol or can be ordered as 
needed should a pathological condition be suspected [48].  The use of magnetic 
resonance imaging (MRI) in pregnancy is possible and can contribute valuable 
information, but clinical use of MRI in pregnancy is still uncommon.  Imaging modalities 
such as x-ray are not recommended for use in pregnancy, except perhaps in 
extraordinary, emergency cases, owing to the increased risk of unfavourable outcomes 
from exposure to ionizing radiation in the fetus [49]. 
1.7.1 Diagnostic Medical Ultrasound 
Diagnostic medical ultrasound is a widely used, non-invasive imaging modality that 
employs non-ionizing energy in the form of sound waves from 2-15 MHz in frequency to 
generate high quality, medically diagnostic images of the internal structures and organs 
of the human body.  Diagnostic medical ultrasound is commonly used for the 
management of uncomplicated and complicated pregnancies alike.  Some advantages of 
diagnostic medical ultrasound include its wide availability, relatively low cost, use of 
non-ionizing energy, relatively high spatial and temporal resolution, and its real-time 
imaging capabilities [50].  Through the use of ultrasound in pregnancy, health care 
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providers can interpret B-mode anatomical images to identify normal and pathological 
findings and make accurate quantitative measurements regarding the size and location of 
fetal and maternal structures. They can also accurately estimate gestational age and fetal 
weight and accurately estimate functional parameters such as blood flow velocity, 
vascular resistance, and vascular pulsatility and waveforms using Doppler ultrasound [1, 
50]. 
 
Ultrasound also has some disadvantages. It is highly operator dependent; it clinically uses 
2-D measurements for image interpretation rather than 3-D volume measurements, which 
more accurately reflect the ground truth [51, 52]; and it provides only limited in vivo 
functional information and no direct metabolic information.  
1.7.2 Fetoplacental Diagnostic Medical Ultrasound Assessment 
The fetoplacental unit is readily assessed using diagnostic medical ultrasound.  As 
pregnancy is by nature a process of growth and development, the routine examination 
protocol and interpretation of image characteristics changes with gestational age. The 
echogenicity and tissue texture of the placenta are qualitatively assessed, and the fetal 
organs and structures are assessed for abnormalities.  Some other common qualitative 
characteristics, such as the placental location in the uterus and fetal orientation, situs, and 
presentation, are also documented.  Quantitative measurements include the crown-rump 
length (CRL), cervical length, distance from the placental edge to the internal os of the 
cervix, abdominal circumference (AC), fetal heart rate (FHR), biparietal diameter (BPD), 
femur length (FL), amniotic fluid index (AFI), and umbilical, ductus venosus, and middle 
cerebral artery (MCA) Doppler measurements.  Late pregnancy assessment via 
ultrasound also includes the assessment of biophysical parameters, such as gross and fine 
fetal motor movements and attempted respiratory movements [1]. All of these 
assessments are made in an attempt to monitor and understand fetoplacental health, but 
much more information, including metabolic and tissue volume information, is required 
that is simply not available with current ultrasound technology and clinical protocols. 
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1.7.3 Magnetic Resonance Imaging 
MRI is an imaging modality that typically relies on the signal generated from the 
displacement and return to thermal equilibrium of the nucleus of a hydrogen atom for its 
image contrast.  However, imaging of nuclei other than hydrogen is possible.  Signal 
generation is achieved by aligning the nuclei in the main magnetic field (B0), with 
subsequent and repeated disruptions to their alignment by a radio-frequency (RF) pulse 
(B1).  The application of an RF pulse causes displacement of protons away from the z-
direction and toward the x-y plane. The z-vector represents, by convention, the direction 
of the B0 magnetic field.  Following the RF pulse, the protons return to thermal 
equilibrium in a process known as relaxation. 
 
Longitudinal relaxation refers to the regrowth of magnetization in the z-direction and its 
return to equilibrium.  The length of time it takes to achieve equilibrium is equal to 5xT1.  
T1  is an intrinsic characteristic of the substance or tissue being imaged.  Transverse 
relaxation refers to the decay of magnetization away from the y- and x-directions.  The 
length of time this takes is known as T2 and T2*.  Transverse relaxation time is affected 
by interactions with nearby protons, and T2* is also affected by inhomogeneities in the 
magnetic field.  While T2 is an intrinsic characteristic of the imaged substance, T2* is 
subject to extrinsic factors such as local field inhomogeneity.  Generally, these tissue 
characteristics form the basis for the multitude of image contrasts that are possible with 
MRI [53]. 
1.7.3.1 Advantages/Disadvantages of MRI 
MRI is a complex, diverse, and flexible imaging modality with many benefits and some 
disadvantages relative to other imaging modalities.  Some disadvantages include high 
cost [54], lack of availability, lack of expertise - specifically in fetal imaging, long 
examination time, sensitivity to motion [55], and suitability for all patient populations in 
terms of patient body habitus and patient safety in a strong magnetic field.  Some benefits 
include a multitude of available image contrasts with adjustable imaging parameters that 
allow the operator or physician to tailor the acquisition to their needs; unsurpassed tissue 
contrast; the capability for reliable 3-D volume acquisitions; its use of non-ionizing 
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energy; its ability to provide structural and functional information about our bodies, 
including metabolism; and its multinuclear capabilities [53, 56, 57]. 
 
While diagnostic medical ultrasound remains the most common imaging modality 
employed throughout pregnancy, the use of MRI- specifically hyperpolarized carbon-13 
(13C) MRI has the potential to provide complementary in vivo metabolic information that 
could serve as a biomarker for fetoplacental health.  
1.7.3.2 Anatomical Imaging 
As previously mentioned, MRI can generate many different image contrasts.  Some of 
these include diffusion-weighted imaging (DWI), proton density (PD) weighting, T2-
weighted (T2-w), and T1-weighted (T1-w).  The weighting of an image contrast refers to 
the tissue characteristics that are allowed to, by manipulation of imaging parameters, 
dominate the resulting image signal intensity.  For example, in a T1-w image, parameters 
such as repetition time (TR) and echo time (TE) can be adjusted to capitalize on the 
effects of T1 while minimizing the effects of T2 on image contrast.  Typically, T1-w 
images provide high resolution, detailed anatomical information, including visualization 
of pathology. T2-w images provide the same type of information as T1-w images, but are 
generated mostly from T2  tissue characteristics and are complementary to T1-w images 
[53].  
1.7.3.3 Carbon-13 (13C) and MRI 
While conventional MRI utilizes the proton within the nucleus of a hydrogen atom to 
generate a signal, it is possible to generate a signal from the protons in the nucleus of 
other elements, such as carbon, which forms the backbone of many biological molecules.  
The natural abundance of carbon-12 (12C) in tissues is 98.93%, similar to the abundance 
of hydrogen (1H) at 99.98% [58].  However, 12C is not visible on MRI due to its lack of 
nuclear spin, but its isotope, 13C, is visible and has previously been exploited in research 
on cancer metabolism. MR imaging with 13C has three main limitations. First, in the 
body, the atomic concentration of carbon is approximately 1/5th of the atomic 
concentration of hydrogen.  Therefore, the signal that can be obtained from carbon can be 
25 
 
no more than 1/5th of the signal that can be obtained from hydrogen, since there are 1/5th 
as many carbon nuclei as hydrogen nuclei present in the body to generate a signal.  
Second, the natural abundance of 13C in the body is extremely low, at 1.11%.  Since the 
MRI signal is proportional to the number of 13C nuclei in an image voxel, the signal 
detected from 13C is substantially lower than the signal that can be detected from 1H.  
Finally, the signal obtained is proportional to the gyromagnetic ratio, which for 13C, is 
roughly one-quarter of the gyromagnetic ratio of 1H (Table 1). Again, this results in very 
low levels of signal from 13C and makes in vivo MR imaging very challenging because 
the 13C signal relative to 1H is approximately equal to 1/5 x 1/100 x 1/4 of the 1H signal 
or 0.05% of the 1H signal [59]. 
Table 1: Comparison between 1H and 13C natural abundance, gyromagnetic ratio, 
and relative signal strength. 
NUCLEUS 1H 13C 
Natural Abundance 99.98% 1.11% 
Gyromagnetic Ratio 
(MHz/T) 
42.58 10.71 
Relative Signal Strength 1 0.0005 
 
1.7.3.4 Hyperpolarized 13C Imaging 
Even though MR has limited sensitivity to endogenous 13C, methods can still be 
employed to take advantage of the biological information that can be obtained from 13C 
MRI.  First, rather than depending on endogenous 13C to generate signal, highly-enriched, 
13C-labelled molecules such as pyruvate can be introduced to the biological system.  
Typically, supra-physiological amounts of the labelled agent are required for distribution 
throughout the tissues of interest.  Additionally, the enriched and labelled agent can be 
hyperpolarized.  Hyperpolarization is the process of enhancing the magnetization of a 
sample. It is achieved by increasing the degree of alignment of the sample’s nuclei within 
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the magnetic field beyond the degree of alignment possible at thermal equilibrium [59].  
Though there are a few methods of hyperpolarization, dynamic nuclear polarization 
(DNP) is used in this thesis.  
1.7.3.4.1 Dynamic Nuclear Polarization (DNP) 
DNP is the transfer of spin polarization from highly polarized electrons to the 
surrounding nuclei.  This polarization is achieved by irradiating the sample containing 
100%-enriched 13C molecules with microwaves at low temperatures (1.4K) and high 
magnetic field strength (3.35T).  This process yields a frozen hyperpolarized sample.  
The frozen hyperpolarized solution must then be warmed rapidly to near body 
temperature by a process referred to as dissolution before in vivo administration. 
Recalling that the MRI signal generated from endogenous, unpolarized 13C is 
approximately 0.05% of the signal that can be generated from 1H, DNP increases the MRI 
signal of hyperpolarized 13C solutions by 10,000-fold when compared to the signal 
possible at thermal equilibrium. Therefore, the process of hyperpolarization via DNP 
increases the signal to levels comparable to 1H MRI, despite the small injected volume of 
the hyperpolarised sample, and makes 13C MRI feasible [59]. 
1.7.3.4.2 [1-13C] Pyruvate 
While it is possible to label most biological molecules with 13C for use as a 
hyperpolarized 13C probe, some practical considerations need to be reviewed.  First, the 
T1 value of the hyperpolarized probe must be long enough to maintain magnetization for 
MRI before the signal decays away to thermal equilibrium.  Second, as a probe of in vivo 
metabolism, the hyperpolarized solution must be rapidly administered to undergo 
metabolism in the tissue of interest before imaging begins.  As such, the T1 value of the 
13C nuclei itself is of critical importance. In 13C-labelled pyruvate, the T1 is on the order 
of tens of seconds.  By the time 3xT1 has elapsed, 95% of the signal has already been lost.  
Therefore, the sample of hyperpolarized solution must be transported to the MRI unit, 
injected, distributed to tissues of interest via the vasculature, and metabolized quickly to 
take full advantage of the signal generated by a hyperpolarized 13C probe.  Lastly, the 
position of the 13C-label on the carbon-based molecule has implications for the observed 
chemical shift of the molecule and alters the metabolic pathways that can be probed.  
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[1-13C] pyruvate (13C label on the C1 carbon position of pyruvate) is the hyperpolarized 
13C probe most commonly used for in vivo metabolic imaging as it addresses the 
challenges listed above. The C1 of pyruvate has a T1 of approximately 65s at 3T. This T1 
is relatively long and ensures sufficient magnetization of the 13C-labelled pyruvate is 
available for signal generation during administration and metabolism. Next, pyruvate is a 
crucial metabolite at the intersection of several critical metabolic pathways. In addition to 
these properties, pyruvate with a single 13C label has a single spectral peak for each of its 
metabolites that are well-separated by chemical shift.  These separated single peaks allow 
for accurate quantification of metabolic conversions from pyruvate to its metabolites. 
 
The use of [1-13C] pyruvate permits the probing of glycolysis as it pertains to the 
conversion of pyruvate to lactate, alanine, and acetyl-CoA via the PDH reaction with CO2 
as a by-product.  It does not, however, allow for probing of the TCA cycle because the 
[1-13C] label does not transfer to the metabolites involved in the TCA cycle as the 
labelled pyruvate is metabolized.  This lack of label transfer to metabolites makes the 
TCA cycle invisible when using a [1-13C] pyruvate solution [59].  To probe the TCA 
cycle, the C2 of pyruvate must possess a 
13C label [60].  
1.7.3.4.3 Hyperpolarized MRI Sequence- BB IDEAL 
There are many different types of MRI sequences designed to capture specific 
information.  To gather metabolic information using a 13C hyperpolarized solution, a 
broadband iterative decomposition of water and fat with echo asymmetry and least-
squares estimation (BB IDEAL) acquisition and reconstruction has proven to be 
effective.  BB IDEAL is a chemical-shift-encoded sequence that is a variation on the 
IDEAL sequence, which ordinarily quantifies the fat and water content of tissues.  For 
this adaptation, instead of separating the signal from fat and water, the BB IDEAL 
reconstruction separates the signal coming from pyruvate, lactate, alanine, and 
bicarbonate based on their known chemical shift using an expanded Dixon method.  BB 
IDEAL MR is a gradient-echo sequence with a spiral-pattern, center-out collection of k-
space data that provides 3-D proton density (PD) weighted images [61].  
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1.7.3.4.4 Area Under the Curve (AUC) 
The AUC is a data analysis method that permits the quantification of rates of metabolism 
of hyperpolarised substrates.  For this thesis, the AUC is the sum-over-time of the PD-
weighted signal for each respective metabolite in a time-resolved data set.  The ratio of 
the AUC for pyruvate to the AUC of each metabolite provides the lactate-, alanine-, and 
bicarbonate-to-pyruvate ratios - the LPR, APR, and BPR, respectively.  These AUC 
ratios represent the relative signal intensity of each metabolite throughout the BB IDEAL 
MR acquisition.  These normalized AUC ratios are directly proportional to the rate 
constants of conversion from pyruvate to lactate, alanine, and bicarbonate, given as the 
kPL, kPA, and kPB, respectively [62].  This proportionality exists because the metabolic 
reactions under examination represent first-order reactions in terms of enzymatic activity. 
A first-order reaction means that the concentration of the catalyzing enzyme is 
proportional to the first power of substrate concentration [catalyzing enzyme] ∝ 
[substrate1].  Thus, the amount of enzymatic activity and resultant metabolite production 
(i.e., lactate, alanine, bicarbonate) is not limited by the amount of substrate (i.e., 
pyruvate) present [63].  
1.8 Objective and Hypothesis 
The objective of this thesis was to investigate the relationship between maternal Western 
diet consumption and placental metabolic function and to quantify metabolic function 
using hyperpolarized 13C MRI in a guinea pig model of pregnancy.  
 
This thesis postulates that lifelong maternal consumption of a Western diet perturbs 
placental metabolic function, resulting in an increase in the conversion rate of pyruvate to 
lactate and alanine (kPL and kPA, respectively) and a decrease in the conversion rate of 
pyruvate to bicarbonate (kPB). 
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Chapter 2  
2 Assessing Mid-pregnancy Placental Metabolism and 
Physical Characteristics in Guinea Pigs Fed a Lifelong 
Western Diet 
In this study, conventional MRI and hyperpolarized 13C MRI were used to assess mid-
pregnancy placental metabolism, appearance, and volume.  Pregnant sows were fed either 
a control or Western diet to ascertain the effects of diet consumption on placental 
metabolism and physical characteristics. 
2.1 Introduction 
Throughout the gestational period, pregnancies can develop complications, which can 
negatively impact the fetoplacental unit.  Some of these complications are related to in 
utero environmental exposures of the fetoplacental unit to external toxins or an 
unfavourable maternal environment.  One factor that has the potential to affect the 
condition of the maternal environment, which ultimately impacts the fetal environment, is 
the consumption of a Western diet [64].   
When challenged, cellular metabolic flexibility enables cells to adaptively utilize 
metabolic pathways to maintain energy status and physiological function [31].  Numerous 
disease states see metabolic flexibility as a hallmark of the physiological and pathological 
alterations affecting cellular function and survival through induction of a “glycolytic 
shift.”  This shift means cells will favour the production of ATP by glycolysis instead of 
ATP production via oxidative phosphorylation [65].  Pyruvate is a central metabolite for 
cellular metabolism. It is produced in the cytoplasm, mainly by glycolysis, and exists in 
equilibrium with alanine and lactate [30]. 
Consumption of a WD, which is high in saturated fat and refined sugar, during pregnancy 
is associated with metabolic and mitochondrial dysregulation in maternal and fetal 
placental compartments at term [66].  This study sought to investigate if a glycolytic 
shift, early in pregnancy, might exist and possibly underlie late-pregnancy metabolic 
dysregulation.  Hyperpolarized 13C MRI techniques have been used to image metabolism 
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in pregnancy[67], but only normal pregnancies were investigated.   Hyperpolarized 13C 
MRI techniques have previously been successfully used to identify a glycolytic shift in 
human prostate cancer studies [68].  If a shift can be identified, technologies, such as 
hyperpolarized 13C MRI, could provide a useful diagnostic tool in determining the 
severity of placental dysfunction and also help to understand the efficacy of treatments 
aimed at modulating the negative impacts of poor diet during pregnancy.  
The development over gestation of placental metabolic processes, particularly pyruvate 
metabolism, are currently poorly understood.  As such, this study aimed to quantify 
changes in the rate of conversion of pyruvate to lactate (kPL), alanine (kPA), and 
bicarbonate (kPB) in a pregnant guinea pig (GP) model. It was postulated that lifelong 
consumption of a WD, in conjunction with pregnancy, would result in an increased mid-
pregnancy placental kPL and kPA and a decreased placental kPB.  This hypothesis was 
derived from the idea that consumption of a WD and subsequent creation of a lipotoxic 
environment may lead to oxidative damage to the placental mitochondria.  This damage 
may alter metabolic processes occurring in the mitochondria, such as the TCA cycle (part 
of aerobic cellular respiration).  Damage to the mechanisms for aerobic cellular 
respiration may lead to increases in glycolytic activity (increases in lactate and alanine 
production) and decreases in aerobic cellular respiratory activity (decreases in 
bicarbonate) [14, 15].  Identifying alterations in placental metabolism may serve as a 
biomarker for fetoplacental metabolic health and provide us with knowledge regarding 
WD-exposed pregnancies not previously available. 
2.2 Methods 
2.2.1 Guinea Pig Model of Pregnancy 
Data from 46 fetoplacental units from 15 pregnant sows, fed either a control or a Western 
diet lifelong, were collected.  These sows were second-generation animals carrying their 
first viable pregnancies determined using diagnostic medical ultrasound.  In this study, 
there were 33 fetoplacental units from 11 WD-fed sows and 13 fetoplacental units from 4 
CD-fed sows.   
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2.2.2 Image Collection 
Each sow underwent MRI at 33 days gestation (~mid term) with a term pregnancy being 
approximately 69 days.  Animals were fasted 2 hours before MRI to ensure a similar 
metabolic state between sows.  They were then given a 0.01mg/kg (body weight) dose of 
glycopyrrolate 30 minutes before MRI via subcutaneous injection to reduce saliva 
production by the sow and reduce the risk of aspiration when under anaesthetic. 
Following the administration of glycopyrrolate, the GPs were anaesthetized using 
isoflurane.  Anaesthesia was induced using a constant flow of 4.5% isoflurane and 
maintained with 1.5-2.5% isoflurane. The GPs were administered 2L/min of 100% O2 for 
the duration of the experiment (~2.5 hours).  An intravenous catheter was inserted into 
the saphenous vein of the left, hind foot to maintain vascular access for the injection of 
the hyperpolarized pyruvate solution.   
The sows were secured in the prone position on a custom-built bed for MRI for the 
duration of the experiment and had their vital signs monitored using an animal 
monitoring kit (Small Animal Instruments, Inc.), containing a rectal thermometer, pulse 
oximeter, ECG leads, and respiratory pillow.  The heart rate and electrocardiogram 
waveform, respiratory rate and respiratory waveform, percentage of oxygen saturation, 
the temperature in degrees Celsius were continuously observed and recorded periodically 
during the MRI scan.  A single ECG lead, coated with electrode gel, was secured to the 
left and right front paws.  The respiratory pillow was placed under the sows on their 
ventral aspect, near the location of the respiratory diaphragm, and a pulse oximeter was 
secured to the right hind foot.  The lubricated thermometer was inserted rectally.  The 
body temperature of the sows was maintained via a water-bath system containing two 
water pads with re-circulated heated water flowing through them.  One pad was secured 
to the custom-built bed, underneath the sows, and the second pad was secured to the 
dorsal aspect of the sows.  Foam earplugs were inserted into the right and left ear canals, 
and protective lubricant was applied to both eyes.   
A series of MRI images were collected using a 3 T MRI (General Electric MR750), 
including T1-w anatomical and BB IDEAL metabolic images. Following MRI, the sows 
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were allowed to recover and were humanely euthanized via CO2 chamber ~48 hours post-
MRI for the collection of fetal and maternal tissues for correlation. 
The anatomical images were acquired with standard 1H MRI, using a 32-coil cardiac 
array for data reception.  The posterior half of the cardiac array was placed under the 
custom-built bed, and the anterior half of the cardiac array was placed over a plastic 
dome covering the sow and custom-built bed.  A 3-D T1-w spoiled gradient echo (SPGR) 
sequence was used to collect anatomical images with a scan time of ~8 minutes.  These 
images served as an anatomical reference for manual segmentation of the placentae. This 
sequence had the following parameters as seen in Table 2: TR=5.1ms, TE=2.4ms, 
resolution=0.88mm, matrix=320 x 320mm, FOV=28 x 19.6cm.  The field of view (FOV) 
was centred over the sow’s abdominal region, ensuring visualization of all fetoplacental 
units. 
Table 2: Summary of T1-weighted imaging parameters. 
IMAGING 
PARAMETERS 
TR (ms) TE (ms) FOV (cm) Matrix 
(mm) 
Resolution 
(mm) 
T1-weighted 
Images 
5.1 2.4 28 x 19.6 320 x 320 0.9 
isotropic 
 
2.2.2.1 Metabolic Images 
Metabolic images were collected using a custom 13C birdcage coil (Morris Instruments).  
Before placing the sow in the 13C coil, the 13C coil was calibrated using the 13C acetate 
phantom signal and a free induction decay (FID) sequence to ensure visualization of the 
13C signal.  The 13C coil was then replaced with the 1H array for anatomical imaging.  
Following anatomical imaging, the 1H array was switched out for the 13C coil in 
preparation for the injection of the hyperpolarized [1-13C] pyruvate solution.  The 13C coil 
was once again calibrated, this time using the signal from endogenous 13C in the sow to 
achieve the most accurate calibration.  Loading the coil with the pregnant sow might have 
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altered the coil’s calibration, so re-calibrating ensured the most accurate calibration for 
data collection.  Following the preparation and administration of the hyperpolarized [1-
13C] pyruvate solution (see details in Section 2.2.3), metabolic images were acquired [61, 
67]. 
A 3-D broadband IDEAL MRI sequence with a hybrid flip angle (HFA) scheme [69] was 
used to collect metabolic images for metabolite quantification and localization within the 
placentae.  Over a 50 second scan time, seven metabolic images with 14 slices each were 
acquired at 7.5s intervals, using the acquisition parameters in Table 3.  The FOV was 
centred over the sow’s abdominal area to ensure the inclusion of all fetoplacental units.  
Table 4 contains the flip angle (FA) for each metabolite at each time point. 
Table 3: Summary of the imaging parameters for the BB IDEAL images. 
IMAGING 
PARAMETERS 
TR 
(ms) 
TE1 
(ms) 
∆TE 
(ms) 
ETL FOV 
(cm) 
Matrix 
(mm) 
Slice 
Thickness 
(mm) 
Resolution 
(mm) 
BB IDEAL 
Images 
16 4.5 1.1 4 20 24 x 
24 
8.5 8.3 in-
plane 
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Table 4: Summary of hybrid flip angle scheme for metabolic image acquisition. 
HYBRID 
FLIP 
ANGLE 
SCHEME 
Time 
Point 1 
FA 
(deg) 
Time 
Point 2 
FA 
(deg) 
Time 
Point 3 
FA 
(deg) 
Time 
Point 4 
FA 
(deg) 
Time 
Point 5 
FA 
(deg) 
Time 
Point 6 
FA 
(deg) 
Time 
Point 7 
FA 
(deg) 
Pyruvate 1.2 1.5 2 2.8 4.6 10 68 
Lactate 1.2 1.6 2.1 3.2 5.4 13.4 88 
Alanine 1.2 1.6 2.1 3.2 5.4 13.4 88 
Bicarbonate 1.2 1.6 2.3 3.6 6.6 20.8 88 
 
2.2.3 Hyperpolarized Injection 
Following anatomical imaging, a 250mM hyperpolarized [1-13C] pyruvate solution, 
prepared via dynamic nuclear polarization using a Hypersense 3.35 T polarizer (Oxford 
Instruments), was dispensed into a flask.  The weight-based dose (75mg/kg body weight), 
plus ~0.2mL, was drawn up in a 5mL syringe by M-E.E and transported to the MRI 
scanner (~30s) by L.M, L.S, or T.W.  The pyruvate solution was then injected into the 
sow as a bolus through the previously inserted intravenous catheter over an ~12s period 
by L.F-W.  The BB IDEAL imaging sequence was initiated manually using the key-pad 
at the bore of the magnet 7.5s after the injection began.  Metabolic images were collected 
over the 50s scan time.  The excess solution collected in the syringe was then flushed 
through the IV set with 0.9% saline, while an FID sequence (~1min scan time) was 
initiated to ensure in vivo hyperpolarization of the 13C signal. 
The excess solution remaining in the flask after dispensation from the polarizer was 
drawn up in a separate 3mL syringe by M-E.E immediately following the collection of 
the weight-based dose, plus ~0.2mL.  The excess solution was injected into the MQC 
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(Oxford Instruments) to ensure adequate polarization. 
2.2.4 Analysis 
Placental volume and characteristics, as well as litter size analyses, were completed using 
the T1-w image acquisitions.   The number of fetoplacental units visualized on MRI was 
determined using the T1-w images and recorded on the experimental protocol form.  BB 
IDEAL image acquisitions were used to analyze metabolic data.  The pregnancy loss rate 
was determined using post-MRI collections data. However, in some instances, loss rate 
data was taken before fetal collections when the pregnancy was lost post-MRI but pre-
collection.  Pregnancy loss was confirmed either by ultrasound or visible discharge of the 
products of conception.  The incidence of abnormal placentae was determined using the 
placental score (see Section 2.2.4.1.1).  Nested statistical analyses were performed on the 
collected data using R (version 4.0.0) [70].  Only placentae having undergone successful 
HFA-metabolic MRI were included in the analyses. 
2.2.4.1 T1-w Analysis 
M-E.E performed manual, full-volume segmentation of each placenta for placental 
localization using the collected T1-w anatomical images and 3D Slicer (version 4.9.0) 
[71-74].  For each placenta, the volume, location relative to the maternal anatomy, and 
placental characteristics (see Section 2.2.4.1.1 below) were recorded. 
2.2.4.1.1 Placental Characteristics and Scoring Analysis 
The placental appearance was qualitatively evaluated and scored using the set of 6 binary 
criteria (score of zero or 1 for each criterion) in Table 5.  These criteria were based on 
observable physical characteristics typical of normally-developed and healthy placentae 
in humans [1] and as observed in the majority of the CD-exposed placentae in the GPs.  
The following criteria were evaluated for each placenta.  The overall visibility (Table 5: 
characteristic i) of each placenta was noted.  A score of zero was given if the placenta 
was readily identified, and all aspects of the placenta were clearly visible and 
differentiated from surrounding tissues.  A score of 1 was given if the placenta was 
poorly visualized and differentiated from surrounding tissue.   
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Next, placental border differentiation (Table 5: characteristic ii) was evaluated.  The 
“border” refers to where the outer placental membrane meets the internal placental 
parenchyma.  Placentae with well-differentiated placental borders were assigned a score 
of zero, and poorly differentiated placental borders were assigned a score of 1.   
The third criterion evaluated the smoothness and regularity of the placental border (Table 
5: characteristic iii).  Smooth and regular borders were given a score of zero, and 
irregular or lobular borders were given a score of 1.  
The next criterion evaluated the homogeneity of the placental parenchyma (Table 5: 
characteristic iv).  Placental parenchyma observed to be homogenous was given a score 
of zero, and heterogeneous placental parenchyma was given a score of 1.   
The fifth criterion evaluated the homogeneity of the MRI signal intensity between the 
placental parenchyma and border (Table 5: characteristic v).  A score of zero was 
assigned if the observable difference in signal intensity between the placental 
parenchyma and border was non-existent or small. A score of 1 was assigned if the signal 
intensity of the placental border was perceived as being markedly hyperintense compared 
to the placental parenchyma.  
 The final criterion assessed was based on whether or not a complete fetoplacental unit 
(fetus and placenta) was readily discernable (Table 5: characteristic vi).  Readily 
discernable fetoplacental units were given a score of zero.  In cases where only a placenta 
could be visualized, a score of 1 was given.  A score of zero indicated a “normal” 
appearing placenta or fetoplacental unit for that particular criterion.  A score of 1 
indicated a deviation from “normal” or an “abnormal” appearing placenta or fetoplacental 
unit for that specific criterion.   
The maximum placental score was six, and the minimum placental score was zero.  An 
overall placental score of zero indicated a normal-appearing fetoplacental unit.  Any 
overall placental score of 1 or more indicated the presence of abnormal observable 
physical characteristics.  Table 5 summarizes the scoring characteristics and the method 
of scoring. 
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Table 5: Summary of placental characteristics and scoring method. 
PLACENTAL 
SCORING AND 
CHARACTERISTICS 
i ii iii iv v vi 
Score=0 Readily 
visible 
Differentiated Regular Homogeneous Homogeneous Yes 
Score=1 Poor 
visibility 
Poor 
differentiation 
Irregular Heterogeneous Heterogeneous No 
Description Overall 
visibility 
Placental 
border 
differentiation 
Placental 
border 
regularity 
Placental 
parenchyma 
homogeneity 
Homogeneity 
between 
placental 
parenchyma and 
border 
Identification 
of complete 
fetoplacental 
unit 
 
2.2.4.2 BB IDEAL Analysis 
The metabolic images were reconstructed from the raw data set using the BB IDEAL 
reconstruction and MATLAB program (version R2019a) [75].  The placental volume 
segmentations generated from the T1-w images were then transferred to and overlaid on 
the reconstructed metabolic images to localize metabolite signals to the placentae.  The 
AUC for pyruvate, alanine, lactate, and bicarbonate was calculated from the flip angle-
adjusted mean metabolite signal intensities (𝑆𝐼𝐹𝐴) in each placental volume at each of the 
seven time-points 𝑡 using Microsoft Excel (2011) according to Equation 1: 
Equation 1: 
𝐴𝑈𝐶𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒 = ∑ 𝑆𝐼𝐹𝐴(𝑡)
𝑡
 
Equation 2: 
𝑺𝑰𝑭𝑨 =
𝑹𝒂𝒘 𝑴𝒆𝒂𝒏 𝑴𝒆𝒕𝒂𝒃𝒐𝒍𝒊𝒕𝒆 𝑺𝑰
𝐬𝐢𝐧(𝑭𝑨)
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Though the AUC assumes a constant flip angle, Equation 2 corrects the signal to account 
for the metabolite-specific variable flip angles used with the HFA sequence.  This 
adjustment means that the AUC ratio is still proportional to the rate constants of 
conversion for the metabolites.   
The AUC ratios for each metabolite were calculated by dividing the AUC for each 
metabolite by the pyruvate AUC. The AUC ratio for each metabolite was assumed to be 
directly proportional to its respective rate constant of conversion from pyruvate to 
metabolite [62].  The AUC ratios for each metabolite were then compared between CD- 
and WD-exposed placentae using nested ANOVA analysis with Satterthwaite’s method, 
with α=0.05. 
2.2.4.2.1 Litter Size, Pregnancy Loss/Success Rate, Incidence 
of Abnormality Analysis 
The litter size for each sow was determined using T1-w images from the time of MRI.  
Any discernible placenta, regardless of its physical characteristics, was included in the 
analysis.  The mean litter size for both diet groups was then calculated by dividing the 
sum of the individual litter sizes by the total number of litters in the respective diet group.  
The litter size for each sow at collection was determined based on collections data and 
included only sows that maintained pregnancy until the time of euthanasia and collection.  
Pups deemed to be live, demised, or resorbing at collection were included in the litter 
size.  The mean litter size was calculated using the same procedure as for the mean litter 
size at MRI.   
The pregnancy loss rate was determined using a combination of post-MRI collections 
data and pre-collections data.  The sum of fetoplacental units deemed to be demised or 
resorbing at the time of collection, in addition to pregnancies lost post-MRI but pre-
collection (determined using litter size at MRI), was taken.  This sum was then divided 
by the total number of placentae from each diet group and multiplied by 100.  The 
pregnancy success rate was determined using collections data.  Pups deemed to be “live” 
at the time of collection were included in this calculation.  The sum of “live” pups at 
collection was divided by the total number of placentae from each diet group and 
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multiplied by 100.  The incidence of abnormal placentae was calculated using the 
placental scores.  Any placenta with a score higher than zero was considered abnormal.  
The sum of abnormal placentae was taken and divided by the total number of placentae in 
the respective diet group and multiplied by 100. 
2.2.4.3 Statistical Analysis 
Nested ANOVA and Welch’s t-test statistical analyses of the data were generated using R 
(version 4.0.0)[70] for the placental score, diet, metabolic, volume and litter size data.   
The nesting method selected (Satterthwaite’s method [76]) for the ANOVA accounted for 
the semi-dependent nature of the placentae within the same litter while avoiding inflating 
the n value artificially.  Graphical representations of the data were generated using 
GraphPad Prism version 8.0.0 for Mac OS X, (GraphPad Software, San Diego, 
California, USA, www.graphpad.com) with α=0.05.  The litter size was analyzed using a 
simple mean calculation, as well as Welch’s t-test.  The loss rate and incidence of 
abnormality were analyzed using a simple percentage calculation.   
2.3 Results 
This section describes the results of the data anaylysis for the metabolic ratios, placental 
score, placental volume, litter size, pregnancy loss rate, and the incidence of placental 
abnormality. 
2.3.1 Metabolite Production 
APR and BPR (but not LPR) were found to vary significantly as a function of placental 
score.  The APR and BPR increased significantly with increases in placental score. No 
significant variation was found in the LPR, APR, or BPR as a function of diet or 
placental volume.  The p-values obtained from the nested ANOVA statistical analyses are 
summarised  in Table 6.  The LPR, APR, and BPR were calculated for every placenta 
included in the metabolic data.  The WD group contained 33 placentae, and the CD group 
contained 13 placentae. The mean and standard deviation for the placental LPR, APR, 
and BPR are summarizd in Table 7.  The distribution of the data for the LPR, APR, and 
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BPR within the diet groups is represented in Figure 6.  The distribution of the data for the 
LPR, APR, and BPR across placental score is represented in Figure 7. 
Table 6: Summary of p-values for nested ANOVA statistical analyses.  The titled 
columns represent contributing factors.  The titled rows represent factors analyzed 
as dependent variables.  * represents a statistically significant p-value 
 
Diet Placental Score Placental Volume 
APR 0.19 0.031* 0.21 
BPR 0.19 0.0061* 0.22 
LPR 0.41 0.10 0.37 
Placental Score 0.08 
 
0.20 
Placental Volume 0.26 0.076 
 
 
Table 7: Summary of the mean and standard deviation for the placental LPR, APR, 
and BPR. 
Metabolic Ratio 
Mean+/-SD 
LPR APR BPR 
Western Diet 0.14+/-0.059 0.10+/-0.050 0.12+/-0.048 
Control Diet 0.11+/-0.048 0.066+/-0.037 0.083+/-0.023 
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Figure 6: A-C. This figure demonstrates the distribution of the LPR (A), APR (B), 
and BPR (C) data in CD- and WD-exposed placentae. No statistically significant 
relationships were detected using a Nested ANOVA.  Data points coded with the 
same colour within a diet group are part of the same litter.   
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Figure 7: A-C. This figure represents the distribution of LPR (A), APR (B), and 
BPR (C) data across placental score. Data points coded with the same colour are 
part of the same litter. Statistically significant variation was detected for the APR 
(B) and BPR (C), but not for the LPR (A) using a Nested ANOVA. 
2.3.2 Placental Score 
The placental score did not vary significantly as a function of diet or placental volume.  
The mean placental score (p= 0.080 for diet, p=0.20 for placental volume) in the WD 
group was 0.91+/-0.88 (33 placentae total) and 0.23+/-0.44 (13 placentae total) in the CD 
group.  The distribution of the placental score data within the diet groups is represented in 
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Figure 8.  Examples of normal and abnormal placental characteristics are demonstrated in 
Figure 9.  Motion artefact is demonstrated in Figure 10.  
 
Figure 8: This figure demonstrates the distribution of the placental score data 
between CD- and WD-exposed placentae.  No statistically significant relationships 
were detected using a Nested ANOVA.  Data points coded with the same colour 
within a diet group are part of the same litter. 
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Figure 9: A-F.  T1-weighted images. A: demonstrates normal placentae.  The white 
arrows indicate normal-appearing placentae. B: demonstrates characteristics i and 
ii from Table 5.  The white arrow indicates a poorly visualized placenta.  The black 
arrow indicates a poorly differentiated placental border. C: demonstrates 
characteristic iii from Table 5.  The white arrow indicates the location of the 
placenta.  The black arrows indicate an irregular placental border. D: demonstrates 
characteristic iv from Table 5.  The white arrow indicates the location of the 
placenta.  The black arrow indicates an area of heterogeneity with increased signal 
intensity relative to the rest of the placenta. E: demonstrates characteristic v from 
Table 5.  The black arrow indicates the location of the placenta.  The white area 
indicates a hyperintense placental border or "halo." F: demonstrates characteristic 
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vi from Table 5.  The white arrow indicates the location of the placenta, and the 
black arrow indicates a hyperintense placental border.  No discernible, associated 
fetus could be identified in this instance.   
 
Figure 10: T1-w image displaying motion artefact over the maternal abdominopelvic 
region.  The white arrows indicate motion artefact both external to the sow and 
within the maternal abdominopelvic structures. 
2.3.3 Placental Volume 
The placental volume did not demonstrate significant variation as a function of diet or 
placental score.  The mean placental volume (p= 0.26 for diet, p=0.076 for placental 
score) in the WD group was 1.6cc+/-0.82 (33 placentae total) and 1.3cc+/-0.22 (13 
placentae total) in the CD group.  Placental volume data distribution within the diet 
groups is represented in Figure 11. 
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Figure 11: This figure demonstrates the distribution of the placental volume data 
between CD- and WD-exposed placentae.  No statistically significant relationships 
were detected using a Nested ANOVA.  Data points coded with the same colour 
within a diet group are part of the same litter. 
2.3.4 Litter Size 
A Welch’s t-test in R (version 4.0.0) was used to analyze the litter size data.  The litter 
size data at MRI and collection is represented in Table 8 and Table 9, respectively. No 
statistically significant differences in litter size at MRI or collection were detected 
between diets (p=0.83 at MRI, p=0.97 at collection).  No statistically significant 
difference was found between the litter size at MRI and the litter size at collection in the 
WD group (p=0.34).  There was no difference between litter size at MRI and litter size at 
collection in the CD group.    
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Table 8: Summary of the mean litter size data at the time of MRI. 
MRI Mean Litter Size 
(pups/litter) 
Standard Deviation Total Litters 
Western Diet (11 
litters) 
3.1 +/-0.88 11 
Control Diet (4 
litters) 
3.3 +/-1.3 4 
 
Table 9: Summary of mean litter size data at the time of tissue collection. 
COLLECTION Mean Litter Size 
(pups/litter) 
Standard Deviation Total Litters 
Western Diet (6 
litters) 
3.5 +/-0.84 6 
Control Diet (4 
litters) 
3.3 +/-1.3 4 
 
2.3.5 Pregnancy Loss Rate 
In the WD group (31 placentae total), 74% of pups were demised or resorbed at the time 
of, or before collection, leaving 26% deemed to be live.  The loss rate in the WD group is 
2.4-fold higher than in the CD group.  In the CD group (13 placentae total), 31% of pups 
were demised or resorbing before or at the time of collection, leaving 69% deemed to be 
live.  The loss rate data is represented in Table 10. 
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Table 10: Summary of loss rate data. 
LOSS RATE Demised/Resorbed 
Fetoplacental Units 
Live Fetoplacental 
Units 
Total Placentae 
Western Diet 74% 26% 31 
Control Diet 31% 69% 13 
 
2.3.6 Incidence of Abnormality 
77% of CD-exposed placentae (13 placentae total) were deemed to be “normal,” and 23% 
were considered “abnormal.”  In the WD group (33 placentae total), 36% of the placentae 
were considered “normal,” and 64% of the placentae were deemed to be “abnormal.”  A 
64% incidence of abnormality represents a 2.8-fold increase in the incidence of 
abnormality when compared to the CD group.  The incidence of abnormality data is 
represented in Table 11. 
Table 11: Summary of the incidence of placental abnormality data. 
INCIDENCE OF 
ABNORMALITY 
Normal Placentae Abnormal 
Placentae 
Total Placentae 
Western Diet 36% 64% 33 
Control Diet 77% 23% 13 
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2.4 Discussion 
2.4.1 Metabolite Production 
No statistically significant variations in metabolism were detected between the CD- and 
WD-fed groups.   The inability to detect such variations was potentially because data 
from only one gestational age was examined.  Data from later gestational ages may 
demonstrate more pronounced variations as fetoplacental needs vary across gestation.  
The use of data from a single gestational age was a limiting factor in this study, and data 
from later gestational ages should be analyzed in the future. Secondly, the small sample 
size, particularly in the CD group, likely impacted the statistical results of the study 
leading to a type II error.  When this study was conceived, it was not clear that nested 
statistical analyses were necessary.  Studies requiring nested statistical analyses typically 
require larger sample sizes.  As such, the results of this study were not sufficiently 
powered to detect statistically significant variations. 
Overall, metabolic, placental score, and volume data from WD-exposed placentae 
demonstrated large variability when compared to CD-exposed placentae. Despite the 
sows having been fed a lifelong WD, this variability may suggest that any potential 
effects and/or the severity of effects from WD consumption are variable between sows 
and between placentae from the same litter.  The in-litter variability of the data implies 
that individual fetoplacental units may respond and adapt differently in a challenging in 
utero metabolic environment.  The difference in response and adaptability between 
fetoplacental units from the same litter may be due to the semi-independent nature of 
fetoplacental units and genetic variation in a multiple-gestation environment.  
Fetoplacental units from the same litter may experience differences in their in utero 
environment.  Most relevant to this study, variations in placental function, mainly 
diffusion, osmosis, and endocrine function, are reported in human studies on multiple 
gestation pregnancies where each fetus has a separate placenta [77].  Another possible 
source of in-litter variation may be related to sex differences between the pups.  Animal 
studies using other rodent models have shown that male pups are more susceptible to 
challenging in utero environments, including maternal diet-related factors, such as high 
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fat and sugar diets.  It is speculated that this increased susceptibility is due to variations in 
placental structure and function of male pups [78]. 
2.4.2 Placental Characteristics and Score 
The placenta is a temporary organ that ages over gestation and functionally declines by 
the end of the gestational period.  However, the placenta can age and decline in function 
prematurely due to exposure to some pathological processes and environmental factors, 
including preeclampsia, tobacco smoking, and diabetes [1].  Premature placental aging 
and decline can lead to deleterious outcomes of pregnancy and might alter placental 
function, including metabolism.  The abnormal physical characteristics observed in the 
placentae are potentially the result of premature placental aging and decline.  The T1-w 
MR characteristics of the placentae were suggestive of placental aging [1]. Some 
characteristics of placental aging were consistent with a pathologist’s findings in 40-day 
and 64-day GA WD-exposed placentae from a separate but similar study from a 
collaborator’s laboratory.   The pathologist (P.K) suggested that the histological findings 
might be suggestive of premature placental aging.  Given the 2.8-fold increase in the 
incidence of abnormality in the WD-exposed placentae, the accelerated aging process of 
the placentae may be due, at least in part, to oxidative stress and formation of reactive 
oxygen species (ROS) induced by consumption of a WD (high fat and sugar).  This 
metabolically toxic environment may damage the placental mitochondria and lead to 
mitochondrial dysfunction.  Faced with chronic oxidative stress and ROS, placental tissue 
may enter cellular senescence.  Cellular senescence is a process that prevents further 
cellular proliferation and regeneration and is a hallmark of cellular aging [79, 80].   
The results presented in this study demonstrated statistically significant increases in the 
APR and BPR when a placenta was identified as having abnormal characteristics.  In 
general, the trend revealed that as placental score increases, so does the APR and BPR.  
The increase in APR in abnormal placentae provides evidence to suggest an increase in 
placental ALT activity in those placentae [81].  When pyruvate and glutamate combine to 
form α-ketoglutarate and alanine as a by-product, ALT is used as the catalyzing enzyme 
[82].  The significance of the increased placental APR in the context of abnormal 
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placental characteristics remains unclear.  However, increases in placental APR may be 
useful as a biomarker of fetoplacental metabolic health. 
Though pyruvate is involved in energy production, in some instances of oxidative stress 
with ROS production, it functions as an antioxidant to neutralize ROS.  As an 
antioxidant, pyruvate interacts with hydrogen peroxide to neutralize the ROS producing 
CO2 and water as by-products.  Though cells attempt to neutralize ROS using pyruvate, 
this process is often ineffective as the stimulus for oxidative stress, and ROS formation 
persists and overwhelms the cells [79].  The production of CO2 (in equilibrium with 
bicarbonate) from the attempted ROS neutralization is potentially the source of the 
increased BPR.  As such, increases in placental BPR may also be useful as a biomarker 
for fetoplacental health. 
Placental scores were assigned to each placenta to indicate the presence or absence of 
observable physical characteristics deemed to be abnormal.  A diverse range of 
characteristics considered abnormal was observed in the placentae of both CD- and WD-
exposed placentae.  While both diet groups contained placentae identified as being 
abnormal, a higher percentage (64%) of WD-exposed placentae were identified as being 
abnormal compared to (23%) of CD-exposed placentae.  It should also be noted that WD-
exposed placentae tended to possess more abnormal characteristics when compared to the 
CD-exposed placentae, leading to higher placental scores (>1) in the WD group.  Several 
WD-exposed placentae were given placental scores of 2 or 3.  The maximum score given 
in the CD group was 1.  From this data, it seemed that maternal consumption of a WD 
had some association with the physical characteristics of the placentae though the nature 
of that association remains unclear.   
Overall poor visibility and differentiation of the placenta from surrounding tissues, as 
well as poor differentiation between the placental border (plates) and parenchyma, may 
be the result of poor or declining placental function.  Tissue differentiation in imaging 
studies is sometimes decreased or lost in the presence of chronic, progressive, or 
inflammatory disease. For example, chronic renal disease with functional loss can lead to 
poor corticomedullary differentiation on MRI as a result of a change in the tissue’s T1 
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value in a disease state [83].  Another possible cause for reduced visibility and 
differentiation and another limitation of this study was the motion artefact from the 
peristalsis of maternal bowel overlying the fetoplacental units.  Active bowel has the 
potential to obscure or limit visualization of underlying and surrounding tissues.  
However, the rater (M-E.E) was careful to identify the presence of motion artefact and 
account for it when assessing the physical characteristics of the placentae.   
An irregular, lobulated placental border is characteristic of an aging, declining placenta in 
humans.  While placental aging and decline is a normal process, environmental insults, 
such as diabetes, can prematurely accelerate the process.  Another characteristic common 
to the placental aging process and other pathological processes, such as hypertension and 
diabetes, is the development of placental infarcts.  Infarcts are areas of tissue that have 
lost their blood supply.  These infarcted areas may calcify or become necrotic [1].  On 
MRI, infarcts may appear as localized areas of hyperintensity.  The presence of infarcted 
placental parenchyma may explain the observation of heterogeneous placental 
parenchyma. 
The observed difference in signal intensity between the placental parenchyma and 
placental border, where the placental border formed a hyperintense “halo” surrounding 
the parenchyma, was potentially the result of a calcified placental border.  Again, 
calcification of the basal and chorionic plates (placental borders) in human beings is part 
of the placental aging process but is concerning when it occurs before the later stages of 
gestation.  Early calcification in the placentae is more likely the result of a pathological 
process rather than the normal, expected placental decline [1].  An alternate explanation 
for the hyperintense “halo” observed in some placentae is proteinaceous edema of the 
placental borders, perhaps due to an inflammatory process.  Pathology reports from a 
collaborator’s laboratory indicated the presence of edema in the chorionic plate of a 64-
day GA WD-exposed placenta.  Though the pathologist (P.K) indicated that 
inflammation was not apparent, there was evidence of cellular debris from macrophages, 
which might suggest an inflammatory process.     
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In one case, a complete fetoplacental unit could not be confidently identified.  However, 
the placenta was identified and segmented for volume, metabolic, and placental score 
data.  This placenta appeared grossly abnormal.  It is possible that the associated fetus 
was demised and had already been resorbed by the sow [84], making the identification of 
a complete fetoplacental unit impossible.  However, it is also possible that the complex 
appearance of a grossly abnormal placenta in combination with often distended, gassy, 
complex, active maternal bowel obscured any potentially viable fetal tissues beyond 
recognition.   
2.4.3 Placental Volume 
As can be seen in Figure 11, there was considerable variation in the WD placental 
volume data when compared to the CD data. This variability may be attributable to 
variation in the effects of a WD on individual placentae within and between litters. 
2.4.4 Litter Size 
The total number of litters in the WD group varied between the mean litter size at MRI 
and the mean litter size at collection calculation because some sows had demonstrably 
lost their pregnancies before collection.  The mean litter size at collection for the WD 
group was increased compared to the mean litter size at MRI because some fetoplacental 
units that were identified at the time of collection were not visualized on MRI.  The 
inability to visualize some fetoplacental units on MRI may have been due to the complex 
appearance of the fetoplacental unit itself. It is also possible that the presence of complex, 
gassy maternal bowel obscured or limited the identification of a fetoplacental unit.  
Overall, the mean litter size between CD- and WD-fed sows was approximately equal, 
suggesting that diet did not affect litter size at 33-days gestation. 
2.4.5 Pregnancy Loss Rate 
For the loss rate calculation, 31 placentae were included instead of 33 placentae as in the 
metabolic data.  Of the 33 placentae, one sow with three placentae was excluded from the 
loss rate calculation because the sow was found deceased post-MRI, and therefore the 
placentae were not included in the loss rate.  One other placenta was added to the loss 
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rate calculation because it was not visualized on MRI but was identified upon collection.   
The 2.4-fold increase in fetoplacental loss in the WD-fed sows when compared to the 
CD-fed sows suggested that WD consumption might have been a factor in the successful 
maintenance of pregnancy.  It could be speculated that the increase in loss rate was 
associated with the 2.8-fold increase in the incidence of placental abnormality in the WD-
fed sows. 
2.4.6 Incidence of Abnormality 
The increased incidence of placental abnormality in the WD-fed sows suggested that WD 
consumption has some relationship with the physical characteristics observed on MRI 
and may contribute to premature placental aging.  Consumption of a WD may also have 
more variable effects in a biological system that are dependent on other factors present in 
that system, accounting for the in-litter variability.   
2.5 Conclusions 
Lifelong consumption of a WD in pregnant GPs did not significantly affect placental 
metabolism, score, or volume.  However, a significant relationship between the placental 
score and the APR and BPR was revealed.  This relationship suggests that observing an 
increase in placental APR and BPR may be useful as a biomarker of fetoplacental health. 
The increased pregnancy loss rate in the WD-fed sows suggests that consumption of a 
WD is somehow associated with increased rates of pregnancy loss.  The increased 
incidence of abnormality in the placentae of WD-fed sows suggests that WD 
consumption may contribute to premature placental aging and have more insidious 
placental effects than previously postulated.   From this study, it is clear that additional 
data is needed to elucidate the relationship between lifelong WD consumption and 
fetoplacental health. 
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Chapter 3  
3 Future Work and Summary 
This section details future work that would help to clarify the relationship between 
lifelong WD consumption and fetoplacental health, such as the assessment of later 
gestational ages, the TCA cycle, and analysis of other fetal organs and tissues that may 
provide valuable information.  A summary of the contents of this thesis is also provided. 
3.1 Future Work 
In Chapter 2, the glycolytic cycle was probed to quantify, indirectly, the conversion of [1-
13C] pyruvate to lactate, alanine, and bicarbonate.  The [1-13C] label was useful for this 
purpose. However, it was a limiting factor in that it was unable to provide critical 
metabolic information regarding the TCA cycle (a part of aerobic cellular respiration) 
because, chemically, the [1-13C] label does not transfer, through metabolic processes to 
the intermediate metabolites involved in the TCA cycle.  In order to probe the TCA 
cycle, a [2-13C] label for pyruvate would be required.  The [2-13C] label on pyruvate does 
metabolize to [5-13C] glutamate.  In a reversible transamination process, glutamate 
converts to α-ketoglutarate- an intermediate metabolite of the TCA cycle.  In this way, 
information about the integrity of the TCA cycle in a challenged metabolic state could 
potentially be investigated.  Future studies employing a hyperpolarized [2-13C] pyruvate 
probe have the potential to broaden our understanding of placental metabolism, 
particularly as an indicator of aerobic cellular respiratory processes [60]. 
As detailed in Chapter 2, the metabolic activity, volume, and appearance of the placenta 
were examined.  While this study provided valuable information regarding the metabolic 
health of the placenta and some of its physical characteristics, it did not examine relevant 
information from some other key metabolically-active organs and tissues. Namely, the 
maternal and fetal livers and adipose tissue were not examined in this study.  
Consumption of a WD likely perturbs metabolism in such a way that metabolic pathways 
might be altered, stimulating ectopic lipid deposition in the fetal and maternal livers 
rather than in subcutaneous fat depots.  Further studies could potentially examine the 
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integrity of the metabolic pathways within the maternal and fetal livers by quantifying the 
conversion of [1-13C]- and [2-13C] pyruvate to its spectrally visible metabolites.  While 
this quantification is possible in the maternal liver, the presence of a metabolic signal in 
the fetal liver must be confirmed in order for this type of study to be feasible.  The 
percentage of fat (or lipid) contained within the fetal and maternal subcutaneous, intra-
abdominal, and intra-organ depots, and the volume of these tissues, should also be 
quantified.  The volume of adipose tissue depots and liver volume can be obtained 
through manual segmentation.  The percentage of fat or lipid in these tissues can be 
determined by quantifying the fat fraction derived from IDEAL (fat and water) MRI 
images.  Qualitatively, tissue and organ appearance should be documented.  The 
collection of this data would provide a more global assessment of maternal and fetal 
metabolic health, as well as provide morphological information regarding these tissues 
and organs. 
Next, in this study, only one gestational age was considered (33-day, mid-gestation).  
Future studies should investigate [1-13C]- and [2-13C] pyruvate metabolism in the 
placenta and maternal and fetal livers (if possible); the volume and appearance of the 
placenta; subcutaneous, intra-abdominal, and intra-organ fat depots; and the fat fraction 
of these fat depots should be documented across gestation.  Specifically, this information 
should be collected for 44-day and 60-day gestational age groups.  This information may 
be useful in determining the progression of metabolic effects related to the consumption 
of a WD, as well as for comparison of metabolic effects between gestational age groups. 
Finally, a major limiting factor of this study was the small sample size, considering the 
need to perform nested statistical analyses and the larger n required for such analyses to 
be accurate.  In the future, additional data should be collected and analyzed in order to 
make confident conclusions about the relationship between diet and placental metabolism 
and characteristics. 
3.2 Summary 
This thesis investigated the effects of lifelong Western diet consumption during 
pregnancy on the placenta in a guinea pig model of pregnancy.  The guinea pig is 
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considered an excellent model of human pregnancy because of its broadly similar fetal 
development and placental structure and function. The placenta is a critical and 
temporary fetal organ that acts as the maternal-fetal interface to support fetal growth and 
development.  The placenta performs immunologic and endocrine functions, as well as 
providing nutrients to the fetus and allowing for gas exchange and waste removal.   
Consumption of a WD, which is high in saturated fats and refined sugars and also 
nutritionally poor, is linked to alterations in fetoplacental metabolic programming, which 
may alter fetoplacental metabolism as an adaptive mechanism for short- and long-term 
survival.  These metabolic alterations are linked to an increase in the lifetime risk that an 
exposed fetus will develop conditions such as CVD, obesity, and type II DM.  It is 
postulated that consumption of a WD may lead to a lipotoxic in utero environment that 
results in the formation of reactive oxygen species and ultimately, oxidative damage to 
the placental mitochondria.  This damage may necessitate the cellular use of alternate, 
less efficient metabolic pathways to meet fetoplacental energy requirements.  As such, 
glycolytic pathways may be favoured over oxidative metabolism in a challenged in utero 
environment.  An increase in glycolytic metabolism would result in increased lactate and 
alanine production and decreased production of markers for oxidative metabolism, such 
as bicarbonate.   
Determining the potential metabolic effects of WD consumption is critical to 
understanding and preserving fetoplacental health.  This relationship is currently poorly 
understood, but MRI imaging techniques, such as hyperpolarized 13C MRI, may be able 
to provide valuable insight into fetoplacental metabolic health.   Hyperpolarized 13C-
labelled pyruvate is a metabolic probe capable of evaluating the metabolic conversion of 
pyruvate to lactate, alanine, and bicarbonate.  AUC ratios to quantify metabolite 
production can be derived from the MR images collected using the hyperpolarized 13C-
labelled pyruvate probe.  These AUC ratios (LPR, APR, and BPR) are directly 
proportional to the metabolic rate constants of conversion from pyruvate to lactate (kPL), 
alanine (kPA), and bicarbonate (kPB).  In conjunction with anatomical T1-w MRI for 
placental localization and characterization, hyperpolarized 13C MRI can indicate 
fetoplacental health status.   
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In Chapter 2, 33-day gestation (~mid term) pregnant sows underwent conventional proton 
and 13C metabolic MRI to investigate the relationship between lifelong WD consumption 
and placental metabolism.  Full-volume segmentations of the placentae were performed, 
and the placentae were characterized using anatomical T1-w MR images.  Metabolite 
AUC ratios, proportional to their respective rate constants of conversion, were quantified 
from the metabolic hyperpolarized 13C-labelled pyruvate images.  A placental score, 
based on placental characterization, was assigned to each placenta.  Mean litter sizes at 
MRI and tissue collection, as well as fetoplacental loss rate and the incidence of placental 
abnormality, were calculated.  A statistically significant relationship was detected 
between the placental score and the APR and BPR but not the LPR.  The APR and BPR 
may be useful as biomarkers of fetoplacental health.  No statistically significant 
relationships were detected between the diet consumed and metabolite production, 
placental score, volume or litter size at MRI and collection. Considerable variability was 
noted in the WD group data between sows and within litters.  Mean litter size was similar 
between diet groups; however, pregnancy loss rate and incidence of placental 
abnormality were increased in WD-exposed pregnancies.  This study was limited by 
small sample size. An additional limitation was the use of data from only one gestational 
age.  Future work should focus on increasing the sample size, including 44-day and 60-
day gestational ages in the data analysis, including other maternal and fetal organs in the 
data analysis, and broadening the investigative scope of the metabolic probes.    
Understanding and preserving fetoplacental health is critical for our short- and long-term 
health, as well as for future generations.   It is clear that continued, focused research is 
necessary to clearly define the relationship between diet and metabolism throughout 
pregnancy. 
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